Clinical assessments were conducted every 3 months to evaluate efficacy, measured as percentage of total weight loss (%TWL), excess weight loss (%EWL), changes in BMI, and improvement in comorbidities, as well as tolerance, monitored for adverse effects including gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) and discontinuation rates
These approaches should be discussed with a healthcare professional to ensure they are appropriate for individual circumstances
GLP-1 Drugs and Bone Loss New research presented at the recent American Academy of Orthopaedic Surgeons on glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) showed adverse concerns on musculoskeletal health
[Smooth Digestion and Comfort] The DigeSEB enzyme blend helps efficiently break down fats, proteins, and carbs to reduce occasional gas, bloating, or heaviness after meals
To reduce nausea, eat smaller, more frequent meals throughout the day rather than three large meals
In off-label discussions, commonly referenced ranges include: Semaglutide: approximately 0.050.125 mg weekly Tirzepatide: below 1 mg weekly For a closer look at typical low-dose ranges, see our tirzepatide microdosing chart
